- Home
- SNAL vs LITS Comparison
SNAL vs LITS Comparison
Compare SNAL & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNAL | LITS |
|---|---|---|
| Founded | 2000 | 2000 |
| Country | United States | United States |
| Employees | 166 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.1M | 25.7M |
| IPO Year | 2022 | 2003 |
Fundamental Metrics
Financial Performance| Metric | SNAL | LITS |
|---|---|---|
| Price | $2.55 | $1.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 52.6K | ★ 308.3K |
| Earning Date | 05-08-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $81,225,622.00 | N/A |
| Revenue This Year | $15.53 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.34 | $0.69 |
| 52 Week High | $5.92 | $2.97 |
Technical Indicators
Market Signals| Indicator | SNAL | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 37.52 | 57.97 |
| Support Level | $2.51 | $0.97 |
| Resistance Level | $3.05 | $1.23 |
| Average True Range (ATR) | 0.16 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 30.65 | 56.83 |
Price Performance
Historical ComparisonAbout SNAL Snail Inc.
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States. The Company has one operating and reportable segment. The company operates in the USA, the UK and Other Countries.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.